Pancreatic Cancer Research

ResearcherUniversity of MissouriActive in the last 2 years

Hao Yuan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1588-0587; OpenAlex author ID A5085761432. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
99
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 5 papers · 2019: 6 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 30

  1. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  2. Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. First author DOI 10.1172/jci191422↗
  3. Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4-HDAC4-RUNX2-GAMT-mediated apoptosis. Co-author DOI 10.1186/s12943-023-01923-7↗
  4. Comprehensive prognostic and immune analysis of a glycosylation related risk model in pancreatic cancer. Last author DOI 10.1186/s12885-023-11725-1↗
  5. SPDEF promotes the classical subtype of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2022.03.18.484951↗
  6. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  7. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  8. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  9. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  10. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  11. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  12. LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. First author DOI 10.3389/fcell.2021.647387↗
  13. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.800268↗
  14. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  15. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  16. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  17. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Co-author DOI 10.1016/j.canlet.2019.04.022↗
  18. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  19. Data on the function of CDH17 in pancreatic cancer growth. Co-author DOI 10.1016/j.dib.2019.104332↗
  20. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗
  21. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-18-0710↗
  22. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  23. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  24. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Co-author DOI 10.1002/ijc.31657↗
  25. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Co-author DOI 10.1159/000491915↗
  26. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  27. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. First author DOI 10.2147/ott.s157759↗
  28. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗
  29. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  30. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 16 shared papers, 2017–2025 · strength 1.79
  2. Qun Chen · 11 shared papers, 2019–2025 · strength 1.37
  3. Peng Shen · 11 shared papers, 2019–2025 · strength 1.37
  4. Yi Miao · 13 shared papers, 2017–2022 · strength 1.17
  5. Lingdong Meng · 9 shared papers, 2019–2025 · strength 1.12
  6. Wanli Ge · 9 shared papers, 2018–2025 · strength 1.08
  7. Xumin Huang · 8 shared papers, 2019–2025 · strength 0.98
  8. Zipeng Lu · 9 shared papers, 2017–2022 · strength 0.84
  9. Taoyue Yang · 6 shared papers, 2021–2022 · strength 0.75
  10. Yi Miao · 5 shared papers, 2019–2025 · strength 0.71
  11. Guodong Shi · 8 shared papers, 2017–2022 · strength 0.68
  12. Pengfei Wu · 7 shared papers, 2017–2022 · strength 0.66
  13. Lei Chen · 6 shared papers, 2017–2025 · strength 0.66
  14. Kuirong Jiang · 5 shared papers, 2018–2024 · strength 0.57
  15. Youngkyu Park · 7 shared papers, 2015–2022 · strength 0.55
  16. David Arthur Tuveson · 7 shared papers, 2015–2022 · strength 0.55
  17. Pengfei Wu · 4 shared papers, 2020–2022 · strength 0.46
  18. Xinjian Liu · 3 shared papers, 2019–2024 · strength 0.38
  19. Giulia Biffi · 5 shared papers, 2015–2021 · strength 0.37
  20. Min Li · 1 shared paper, 2025 · strength 0.37
  21. Qun Chen · 1 shared paper, 2025 · strength 0.37
  22. Guangfu Li · 3 shared papers, 2019–2021 · strength 0.36
  23. Baobao Cai · 3 shared papers, 2018–2022 · strength 0.32
  24. Tobiloba E. Oni · 4 shared papers, 2015–2021 · strength 0.30
  25. Ela Elyada · 4 shared papers, 2015–2021 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.